X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs CIPLA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA CIPLA GSK PHARMA/
CIPLA
 
P/E (TTM) x 61.6 33.1 186.0% View Chart
P/BV x 11.5 2.9 399.0% View Chart
Dividend Yield % 2.5 0.6 426.0%  

Financials

 GSK PHARMA   CIPLA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
CIPLA
Mar-18
GSK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,760663 416.3%   
Low Rs2,040479 425.9%   
Sales per share (Unadj.) Rs339.0189.0 179.3%  
Earnings per share (Unadj.) Rs41.417.6 235.4%  
Cash flow per share (Unadj.) Rs45.934.0 134.9%  
Dividends per share (Unadj.) Rs35.003.00 1,166.7%  
Dividend yield (eoy) %1.50.5 277.6%  
Book value per share (Unadj.) Rs242.9176.7 137.4%  
Shares outstanding (eoy) m84.70805.12 10.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.13.0 234.4%   
Avg P/E ratio x57.932.5 178.6%  
P/CF ratio (eoy) x52.316.8 311.5%  
Price / Book Value ratio x9.93.2 305.8%  
Dividend payout %84.517.1 495.6%   
Avg Mkt Cap Rs m203,280459,724 44.2%   
No. of employees `000NA23.6 0.0%   
Total wages/salary Rs m5,23426,901 19.5%   
Avg. sales/employee Rs ThNM6,446.1-  
Avg. wages/employee Rs ThNM1,139.4-  
Avg. net profit/employee Rs ThNM600.0-  
INCOME DATA
Net Sales Rs m28,715152,193 18.9%  
Other income Rs m5453,577 15.3%   
Total revenues Rs m29,260155,769 18.8%   
Gross profit Rs m5,05928,264 17.9%  
Depreciation Rs m38013,228 2.9%   
Interest Rs m21,142 0.2%   
Profit before tax Rs m5,22217,470 29.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m178-775 -23.0%   
Tax Rs m1,8922,501 75.6%   
Profit after tax Rs m3,50814,166 24.8%  
Gross profit margin %17.618.6 94.9%  
Effective tax rate %36.214.3 253.1%   
Net profit margin %12.29.3 131.3%  
BALANCE SHEET DATA
Current assets Rs m21,815108,141 20.2%   
Current liabilities Rs m15,99938,322 41.7%   
Net working cap to sales %20.345.9 44.2%  
Current ratio x1.42.8 48.3%  
Inventory Days Days6497 65.5%  
Debtors Days Days1974 25.1%  
Net fixed assets Rs m12,475109,411 11.4%   
Share capital Rs m8471,610 52.6%   
"Free" reserves Rs m19,726140,682 14.0%   
Net worth Rs m20,573142,292 14.5%   
Long term debt Rs m636,621 0.0%   
Total assets Rs m39,475228,606 17.3%  
Interest coverage x2,612.016.3 16,030.9%   
Debt to equity ratio x00.3 0.1%  
Sales to assets ratio x0.70.7 109.3%   
Return on assets %8.96.7 132.8%  
Return on equity %17.110.0 171.3%  
Return on capital %26.210.0 263.7%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56451,691 1.1%   
Fx outflow Rs m7,42921,033 35.3%   
Net fx Rs m-6,86530,658 -22.4%   
CASH FLOW
From Operations Rs m4,72814,628 32.3%  
From Investments Rs m-1,042-8,540 12.2%  
From Financial Activity Rs m-3,066-3,855 79.5%  
Net Cashflow Rs m6202,431 25.5%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 50.7 20.8 243.8%  
Indian inst/Mut Fund % 10.2 12.2 83.6%  
FIIs % 23.8 23.7 100.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 15.4 26.2 58.8%  
Shareholders   102,036 161,166 63.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 192 Points Higher; Energy and IT Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended higher. Gains were seen in the energy sector, IT sector.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

This Trend Will Produce a Once in a Lifetime Opportunity to Buy Stocks(The 5 Minute Wrapup)

Jan 15, 2019

Unlike his habit of pouring out stock wisdom in his annual letters to shareholders, Buffett spoke of this trend only once every few decades.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

My Next Small Cap Recommendation Is Practically a 'No Brainer'(Profit Hunter)

Jan 14, 2019

With a strong debt free balance sheet in its favour, attractive dividends and trading at almost lifetime lows, this investing idea is almost a no brainer.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 21, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - UNICHEM LAB COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS